ADC Payload Summit

The ADC payload landscape is shifting rapidly. Driven by clinical successes of lower potency topoisomerase I inhibitors and as payloads that elicit novel modes of action continue to gain momentum, ADC developers are looking to harness these payload technologies to diversify the mechanism of action, widen the therapeutic index and expand the disease indications that ADCs can see a benefit in.

As part of the World ADC Series, the ADC Payload Summit will deep dive into how you can alter the chemistry of well-explored payloads to see an enhanced therapeutic effect, explore novel cytotoxic payloads that provide a new way to kill cancer cells and evaluate the challenges and opportunities that lower potency and non-oncology payloads offer. This unique forum will equip you with the know-how to make the biggest impact on your ADCs efficacy through your payload R and D.

As the first and only conference exclusively focusing on ADC Payloads, this is your opportunity to join 60+ of your peers working in Chemistry, Medicinal Chemistry and Discovery to uncover how using structure-activity relationship studies can optimize traditional topoisomerase I inhibitors, tubulin inhibitors and DNA damaging agents, explore novel mechanisms of action from oligonucleotide, degrader, RNA polymerase and NMT payloads, and understand how payload choice impacts linker and conjugation strategies.

Prices:
Drug Developer Pricing - Conference Only - On The Door: USD 2999.00,
Drug Developer Pricing - Conference + Pre-Conference Workshop Day - On The Door: USD 4197.00,
Solution Provider Pricing - Conference Only - On The Door: USD 3699.00,
Solution Provider Pricing - Conference + Pre-Conference Workshop Day - On The Door: USD 5097.00,
Academic Pricing - Conference Only - On The Door: USD 2599.00,
Academic Pricing - Conference + Pre-Conference Workshop Day - On The Door: USD 3597.00

Speakers: David Thurstonz, Professor - Drug Discovery, King's College London School of Medicine, Francesca Zammarchi, Chief Scientific Officer, Myricx Bio, Hendrik Grub, Director, Chemistry, Heidelberg Pharma, Hong Myung Lee, Principal Scientist, Takeda Pharmaceutical Co. Ltd., James Palacino, Head of Research, Orum Therapeutics, Kashif Khan, Director, Medicinal Chemistry, Tumor Targeted Delivery, AstraZeneca, Krishna Bajjuri, Senior Director - Chemistry, Sutro Biopharma, Mano Manoharan, Senior Vice President - Innovation Chemistry and Alnylam Distinguished Scientist, Alnylam Pharmaceuticals, Marc-Andre Kasper, Vice President Chemistry and Early Discovery, Tubulis GmbH, Marcel Rieker, Senior Scientist, Merck KGaA, Rajkumar Genesan, Executive Director, Oncology Research, Amgen, Romas Kudirka, Director of Chemistry and Bioconjugation, Bolt Biotherapeutics, Shou-Ching Jaminet, Founder, Angiex, Vishwas Paralkar, Chief Scientific Officer, Cybrexa Therapeutics, Yves Pommier, Senior Investigator and Head Of Molecular Pharmacology Group, National Cancer Institute, Zhaohui Sunny Zhou, Professor and Faculty Fellow, Northeastern University

Others Details

Brochure: https://go.evvnt.com/2225021-3?pid=6581